62. Paroxysmal nocturnal hemoglobinuria Clinical trials / Disease details
Clinical trials : 271 / Drugs : 163 - (DrugBank : 49) / Drug target genes : 22 - Drug target pathways : 106
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01194804 (ClinicalTrials.gov) | April 2008 | 30/8/2010 | E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients | Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Extension Study to C07-001 Protocol | Paroxysmal Nocturnal Hemoglobinuria | Drug: Eculizumab | Alexion Pharmaceuticals | CMIC Co, Ltd. Japan | Completed | 12 Years | N/A | All | 27 | Phase 2 | NULL |
| 2 | NCT01192399 (ClinicalTrials.gov) | November 2007 | 30/8/2010 | Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients | Phase II Clinical Study of Eculizumab (h5G1.1-mAb) in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients | Paroxysmal Nocturnal Hemoglobinuria | Biological: Eculizumab | Alexion Pharmaceuticals | NULL | Completed | 12 Years | N/A | All | 29 | Phase 2 | NULL |
| 3 | EUCTR2005-000043-28-IT (EUCTR) | 01/09/2005 | 06/02/2007 | A Phase III Open label extension study of Eculizumab in patients with transfusion dependent hemolytic paroxysmal nocturnal hemoglobinuria PNH who have participated in Triumph C04-001 , Shepherd C04-002 or X03-001 studies | A Phase III Open label extension study of Eculizumab in patients with transfusion dependent hemolytic paroxysmal nocturnal hemoglobinuria PNH who have participated in Triumph C04-001 , Shepherd C04-002 or X03-001 studies | paroxymal nocturnal hemoglobinuria MedDRA version: 6.1;Level: PT;Classification code 10034042 | Product Name: Eculizumab Product Code: h5G1.1-mAb Product Name: Eculizumab Product Code: h5G1.1-mAb | ALEXION PHARMACEUTICALS INC | NULL | Not Recruiting | Female: yes Male: yes | 170 | Phase 3 | Germany;United Kingdom;Spain;Ireland;Italy;Sweden |